Big News from New Day Diagnostics! We’re proud to announce the nationwide launch of ColoHealth our FDA-cleared blood test for colorectal cancer screening, now available for physician ordering across the U.S.
ColoHealth is a game-changer in early detection—simple, accurate, non-invasive—and empowers providers to offer patients a more accessible screening option.
NDD ist dran am next-gen Test der von Epigenomics übernommen wurde. Mal sehen…….
„At ADLM 2025, meet us at the Luminex booth ) where we’ll be talking about how the Luminex ELISA platform powers our work- from developing ColoPlex Plus a next-gen blood test for early colorectal cancer detection, to designing custom assays for diagnostics developers.
Through New Day Bioresearch, we offer contract research services that help bring your vision to life- from assay design to analytical validation.
Mogli3
: NDD macht ernst mit NextGen von Epigenomics
ColoHealth ist der alte Test von Epigenomics, ColoPlex Plus der neue Test NextGen von Epigenomics.
„Having a great showcase for ColoHealth and (coming soon!!) ColoPlexPLUS at Association for Diagnostics & Laboratory Medicine ADLM2025 with our amazing clinical oncology partner Luminex booth 1431!“ Bin dann mal gespannt wenn dieser neue Test auf den Markt kommt.